Pharmacokinetics, pharmacodynamics and safety of QGE031 (ligelizumab), a novel high-affinity anti-IgE antibody, in atopic subjects

BACKGROUND: Using a monoclonal antibody with greater affinity for IgE than omalizumab, we examined whether more complete suppression of IgE provided greater pharmacodynamic effects, including suppression of skin prick responses to allergen. OBJECTIVE: To explore the pharmacokinetics, pharmacodynamic...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Exp Allergy
Main Authors: Arm, J P, Bottoli, I, Skerjanec, A, Floch, D, Groenewegen, A, Maahs, S, Owen, C E, Jones, I, Lowe, P J
Formato: Artigo
Idioma:Inglês
Publicado em: BlackWell Publishing Ltd 2014
Assuntos:
Original Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4278557/
https://ncbi.nlm.nih.gov/pubmed/25200415
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cea.12400
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados